Implanet received FDA 510(k) clearance and CE Mark approval for the Jazz Claw®, a hybrid-implant designed to treat degenerative spinal pathologies in adults, including kyphosis.
The Jazz Claw seeks to provide autostable posterior fixation by replacing traditional hook-and-screw fixation systems.
The addition of Jazz Claw contributes to Implanet’s product portfolio for the treatment of degenerative spinal pathologies. Earlier this quarter, the company received regulatory approval for the Jazz Lock Implant.
Implanet received FDA 510(k) clearance and CE Mark approval for the Jazz Claw®, a hybrid-implant designed to treat degenerative spinal pathologies in adults, including kyphosis.
The Jazz Claw seeks to provide autostable posterior fixation by replacing traditional hook-and-screw fixation systems.
Implanet received FDA 510(k) clearance and CE Mark approval for the Jazz Claw®, a hybrid-implant designed to treat degenerative spinal pathologies in adults, including kyphosis.
The Jazz Claw seeks to provide autostable posterior fixation by replacing traditional hook-and-screw fixation systems.
The addition of Jazz Claw contributes to Implanet’s product portfolio for the treatment of degenerative spinal pathologies. Earlier this quarter, the company received regulatory approval for the Jazz Lock Implant.
You are out of free articles for this month
Subscribe as a Guest for $0 and unlock a total of 5 articles per month.
You are out of five articles for this month
Subscribe as an Executive Member for access to unlimited articles, THE
ORTHOPAEDIC INDUSTRY ANNUAL REPORT and more.
Copy to clipboard 
